STOCK TITAN

Applied Therapeutics, Inc. - APLT STOCK NEWS

Welcome to our dedicated page for Applied Therapeutics news (Ticker: APLT), a resource for investors and traders seeking the latest updates and insights on Applied Therapeutics stock.

Applied Therapeutics, Inc. (Nasdaq: APLT) is a clinical-stage biopharmaceutical company headquartered at 3104 Cherry Palm Dr, Tampa, FL. The company focuses on creating novel drug candidates targeting validated molecular markers for diseases with high unmet medical needs.

Currently, the company has several promising compounds in its pipeline. The lead candidate is govorestat (AT-007), a central nervous system penetrant Aldose Reductase Inhibitor (ARI) designed to treat rare metabolic diseases like Classic Galactosemia, SORD Deficiency, and PMM2-CDG. Govorestat has shown significant clinical benefits in reducing toxic metabolites like galactitol and sorbitol, leading to improvements in activities of daily living, cognitive skills, and motor functions in both adult and pediatric patients.

In recent achievements, Applied Therapeutics has completed Phase 3 trials for govorestat in treating Classic Galactosemia and SORD Deficiency, receiving Priority Review status for its New Drug Application (NDA) from the U.S. FDA. The company has also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA). Additionally, Applied Therapeutics is preparing for the commercial launch of govorestat upon potential approval by regulatory authorities.

Other key pipeline candidates include AT-001 for Diabetic Cardiomyopathy (DbCM) and AT-003 for Diabetic Retinopathy. AT-001 has shown favorable results in stabilizing cardiac functional capacity in patients with DbCM and is safe and well-tolerated. AT-003, still in preclinical development, is designed to address diabetic retinopathy.

Financially, Applied Therapeutics reported strong progress, raising $100 million in a private placement to extend its cash runway into 2026. This funding supports its clinical and commercial activities, ensuring sustained growth and development.

To learn more about Applied Therapeutics, visit their official website at www.appliedtherapeutics.com and follow them on Twitter @Applied_Tx.

Rhea-AI Summary

Applied Therapeutics, a clinical-stage biopharmaceutical company, has announced a definitive securities purchase agreement for the private placement of 9,735,731 shares of common stock at $0.946 each and 22,000,000 pre-funded warrants at $0.945, with gross proceeds expected to total approximately $30 million. This transaction is led by Venrock Healthcare Capital Partners and is set to close around April 26, 2023. The funds will be allocated to research and development, pipeline candidate registration, and general corporate purposes, extending the company's operational runway through mid-2024. The securities are not registered under the Securities Act and will require a registration statement for resale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.28%
Tags
none
-
Rhea-AI Summary

Applied Therapeutics (Nasdaq: APLT) announced positive results from the ACTION-Galactosemia Kids trial for govorestat, a treatment for Galactosemia. The trial demonstrated long-term clinical benefits in improving daily activities, behavior, cognition, and motor skills compared to placebo. Although not statistically significant on the primary endpoint, systematic improvements were observed. The company plans to request a pre-NDA meeting with the FDA and submit a Marketing Authorization Application with the EMA in mid-2023. Approximately 3,000 patients in the US and 4,000 in the EU suffer from Galactosemia, indicating a significant market need.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.28%
Tags
none
-
Rhea-AI Summary

Applied Therapeutics reported progress in three Phase 3 trials, focusing on crucial unmet medical needs. Notably, the company announced positive interim results from the Phase 3 INSPIRE trial, showing a 52% reduction in sorbitol levels with AT-007 in patients with SORD Deficiency. The company also partnered with Advanz Pharma for commercialization in Europe, with potential milestone payments exceeding €130 million. Financially, cash reserves dropped to $30.6 million, while net loss improved to $82.5 million, or $2.18 per share, down from $105.6 million. Overall, the company is positioned for upcoming data readouts in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.62%
Tags
Rhea-AI Summary

Applied Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: APLT), will participate in the Neuromuscular & Bone Panel at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 2:10 p.m. ET in Boston. This participation highlights the company’s ongoing commitment to addressing high unmet medical needs.

The event will be accessible via webcast on their Investor Relations page, with a replay available afterward. Applied Therapeutics is advancing novel drug candidates, including AT-007 for CNS rare metabolic diseases and AT-001 for Diabetic Cardiomyopathy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.87%
Tags
conferences
-
Rhea-AI Summary

Applied Therapeutics announced positive results from the ongoing Phase 3 INSPIRE trial for AT-007 in patients with SORD Deficiency. The trial is assessing the drug's effect on sorbitol reduction and clinical outcomes among approximately 50 patients aged 16-55 in the US and Europe. AT-007 demonstrated a significant mean sorbitol reduction of 52% (approximately 16,000 ng/ml) over 90 days compared to placebo (p<0.001). The company is collaborating with the FDA to determine the regulatory pathway for a New Drug Application (NDA). Continued monitoring will assess clinical outcome measures over 12 to 24 months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17%
Tags
-
Rhea-AI Summary

Applied Therapeutics (Nasdaq: APLT) will present virtually at the SVB Securities Global Biopharma Conference on February 16, 2023, at 2:20 p.m. ET. Interested parties can access the webcast via the Events page on the company's investor relations website, with a replay available afterward.

The company focuses on developing novel drug candidates targeting high unmet medical needs. Its lead candidate, AT-007, aims to treat CNS rare metabolic diseases, while AT-001 targets Diabetic Cardiomyopathy. Preclinical development includes AT-003 for Diabetic Retinopathy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
conferences
Rhea-AI Summary

Applied Therapeutics (APLT) has partnered with Advanz Pharma to commercialize AT-007 in Europe for Galactosemia and SORD Deficiency. The deal includes milestone payments exceeding €130 million and a 20% royalty on future net sales. This partnership is expected to enhance Applied Therapeutics' capital position and extends its cash runway through critical milestones. Advanz will oversee the packaging and distribution, while Applied Therapeutics remains responsible for development and manufacturing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.29%
Tags
partnership
-
Rhea-AI Summary

Applied Therapeutics (NASDAQ: APLT) reported its Q3 2022 financial results, with significant advancements in its pipeline, including full enrollment in Phase 3 trials for AT-001 in Diabetic Cardiomyopathy and encouraging trends in the ACTION-Galactosemia Kids trial for AT-007. Cash and equivalents stood at $47.4 million, down from $80.8 million at year-end 2021. R&D expenses decreased to $13.1 million from $17.6 million year-over-year, while G&A expenses fell to $6.2 million from $10.8 million. The net loss narrowed to $19.1 million, or $0.40 per share, compared to a $28.4 million loss in Q3 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.58%
Tags
-
Rhea-AI Summary

Applied Therapeutics (Nasdaq: APLT) reported promising preclinical data supporting its investigational treatment, AT-001, for Diabetic Cardiomyopathy. Key findings show AT-001 effectively reduces cardiac fibrosis and prevents adverse remodeling. The ongoing Phase 3 ARISE-HF study emphasizes the importance of cardiac functional capacity, measured by Peak VO2, for patients' quality of life. This data will be presented at the American Heart Association Scientific Sessions from November 5-7, 2022, alongside additional insights into Diabetic Cardiomyopathy's diagnosis and prevalence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.76%
Tags
none
Rhea-AI Summary

Applied Therapeutics has announced the full enrollment of 675 patients in the Phase 3 ARISE-HF trial, evaluating AT-001 for treating Diabetic Cardiomyopathy (DbCM). This study, which is placebo-controlled and double-blinded, aims to measure cardiac functional capacity after 15 months. DbCM affects about 20% of Type 2 Diabetes patients, representing a substantial market opportunity. If successful, AT-001 could become the first approved treatment for DbCM. Topline data is expected by early 2024, with plans for additional long-term data collection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.92%
Tags

FAQ

What is the current stock price of Applied Therapeutics (APLT)?

The current stock price of Applied Therapeutics (APLT) is $0.8667 as of December 23, 2024.

What is the market cap of Applied Therapeutics (APLT)?

The market cap of Applied Therapeutics (APLT) is approximately 95.2M.

What is the primary focus of Applied Therapeutics, Inc.?

Applied Therapeutics focuses on developing novel drug candidates against validated molecular targets for diseases with high unmet medical needs.

What is govorestat (AT-007)?

Govorestat is a CNS penetrant Aldose Reductase Inhibitor developed for treating rare metabolic diseases like Classic Galactosemia, SORD Deficiency, and PMM2-CDG.

What are the recent achievements of Applied Therapeutics?

Recent achievements include completing Phase 3 trials for govorestat, obtaining FDA Priority Review status for its NDA, and submitting an MAA to the EMA.

What other drugs are in the Applied Therapeutics pipeline?

The pipeline includes AT-001 for Diabetic Cardiomyopathy and AT-003 for Diabetic Retinopathy.

How is govorestat expected to benefit patients with Galactosemia?

Govorestat reduces plasma galactitol levels, improving activities of daily living, cognitive skills, and motor functions in patients with Galactosemia.

What recent financial activities has Applied Therapeutics undertaken?

Applied Therapeutics raised $100 million in a private placement to extend its cash runway into 2026, supporting clinical and commercial activities.

What is the status of govorestat's regulatory review?

Govorestat's NDA is under Priority Review by the FDA with a PDUFA target action date of November 28, 2024. Its MAA is under review by the EMA.

Where is Applied Therapeutics headquartered?

Applied Therapeutics is headquartered at 3104 Cherry Palm Dr, Tampa, FL, United States.

What are AT-001 and AT-003 intended to treat?

AT-001 is developed for Diabetic Cardiomyopathy, and AT-003 is intended for the treatment of Diabetic Retinopathy.

How can I learn more about Applied Therapeutics?

You can learn more by visiting their website at www.appliedtherapeutics.com and following them on Twitter @Applied_Tx.

Applied Therapeutics, Inc.

Nasdaq:APLT

APLT Rankings

APLT Stock Data

95.25M
102.11M
5.24%
101.91%
11.66%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK